Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
about
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsPractical aspects of NGS-based pathways analysis for personalized cancer science and medicineCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicineTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsDatabases and web tools for cancer genomics studyIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesApoptotic agentsThe proteomic landscape of triple-negative breast cancer.Therapeutic targeting of cancers with loss of PTEN function.Biological Networks for Cancer Candidate Biomarkers DiscoveryApproaches to modernize the combination drug development paradigmToward precision medicine of breast cancerSETD2: an epigenetic modifier with tumor suppressor functionalityUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyExploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationLeveraging systems biology approaches in clinical pharmacologyAnalysis of individual protein regions provides novel insights on cancer pharmacogenomicsIntegrated analysis of transcriptome in cancer patient-derived xenograftsDiscovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical ModelingA Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning PredictionsHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BA Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity PredictionIntegrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell LinesIntegrative network modeling approaches to personalized cancer medicineInferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic propertiesRepositioning approved drugs for the treatment of problematic cancers using a screening approach.COSMIC: exploring the world's knowledge of somatic mutations in human cancerWhat's that gene (or protein)? Online resources for exploring functions of genes, transcripts, and proteins.A community effort to assess and improve drug sensitivity prediction algorithms.NCI-60 Cell Line Screening: A Radical Departure in its Time.mutLBSgeneDB: mutated ligand binding site gene DataBase.The 2013 Nucleic Acids Research Database Issue and the online molecular biology database collection.Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.PiHelper: an open source framework for drug-target and antibody-target data.An unbiased metric of antiproliferative drug effect in vitro.DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition dataImpact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response data.MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cellsHow Consistent are Publicly Reported Cytotoxicity Data? Large-Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements.
P2860
Q24294914-23FC071F-BA78-4086-8245-5E0C4C460ACFQ26748603-3C5B21BD-73F0-4B4B-AA04-931CC935BE0AQ26800337-F82A4402-06DE-4748-97EE-13A901C3B04DQ26801410-80650B87-C1D6-49B1-9651-5FF993B9566EQ26999404-50E9B266-BE6C-4623-9AF4-E65AC3186043Q27014174-A764ABAE-D01B-432C-AE9B-C023BB6AE07DQ27016160-8579EAFA-B624-45AB-A008-0AEC527704DDQ27320721-DCAA79CF-F50E-428A-B819-7332ACF6FB9EQ27852764-C15E8BF3-C8FA-4D37-BD94-166D32872016Q28068983-E37BA02C-5D34-407C-98E7-3E4442209D87Q28072074-D4F8BB8C-44E7-4348-967B-F0C84D952FA7Q28073967-3E980E99-54FE-4B81-B393-7484A2731AF6Q28075731-3903B904-BD10-4CF4-9BC6-6F3CDD28B3AFQ28076097-DAA1C132-B7F3-4AFE-8297-5C57B79CC48CQ28118450-DBAD89F2-72C6-476F-AE05-AF9BFE82544AQ28539118-FCAD5C98-88D6-43ED-BCF1-6FA7E3D48D39Q28542982-9E24BCD1-D7AF-463D-8017-680387587E5AQ28547069-A86B8695-9A4D-4F93-8C45-D51852A2D424Q28547862-C5E4AB35-12AD-4193-8074-54C0E4306E77Q28550159-3255847C-DD4D-4B05-9697-C7997436AFEFQ28551145-EE6BD310-5591-480F-B1BA-C343955FBCFEQ28551596-CAB5FA35-003C-4AE8-BF20-09AC8AB8CEDFQ28553930-EBDB7D15-E9DF-49AE-8288-61C029B397D0Q28602016-7C52F635-45B2-4A19-A064-0835B79E96D2Q28829729-2656E5EA-4A31-4DE5-BF86-4D08D16369EDQ29248487-B7CEBF48-BB0D-4E11-8122-909195739F98Q29615725-DF70D1D1-2E92-4E09-9222-A893157F2EAAQ30361280-9C2BC888-B71A-4E06-B076-3F7BF75BDD58Q30371323-E032068C-9B0B-49DE-B104-22DB84C24066Q30383428-C235114A-531D-4556-BCA3-C0B5C4B256CAQ30395862-DFDAFE55-1C5E-42AA-BF67-2B473C0E78CFQ30424320-C735670C-746D-4847-B19F-70EA538DDD34Q30490446-92E41197-378F-4910-A3EA-04F11737A410Q30648106-2ED5F931-CE5E-42CE-A0B3-7E7FDE6A8A58Q30763539-B0A54502-36AD-4FFC-895C-8259CFFDF7F8Q30837199-2990416C-BA82-452D-813E-7A85FE4B9397Q30982375-B5029690-D099-4168-84D6-56B3B7A59204Q30985881-37FE8F46-7C84-486B-9B4D-31B46DBB9765Q31012806-AFAD60D7-46DF-4D67-A22B-49FA90425F36Q31018677-9162375D-44C0-47A5-8A4F-2B0C227CF2AE
P2860
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@ast
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@en
Genomics of Drug Sensitivity in Cancer
@nl
type
label
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@ast
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@en
Genomics of Drug Sensitivity in Cancer
@nl
prefLabel
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@ast
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@en
Genomics of Drug Sensitivity in Cancer
@nl
P2093
P2860
P50
P356
P1476
Genomics of Drug Sensitivity i ...... ker discovery in cancer cells.
@en
P2093
Cyril Benes
Daniel A Haber
Dave Beare
Elena J Edelman
I Richard Thompson
Jorge Soares
Mathew J Garnett
Nidhi Bindal
Patricia Greninger
Simon Forbes
P2860
P304
P356
10.1093/NAR/GKS1111
P407
P433
Database issue
P577
2012-11-23T00:00:00Z